Unlike in the West where 85–90% of the OI patients seeking medical treatments were affected by COL1A1/2 mutations [28, 29], our cohort and others in China consistently included 2/3–3/4 of such patients only [30]. The gene discussed is COL1A1; the disease is osteogenesis imperfecta.